Research
Hormonal
A specific outer membrane protein from Akkermansia muciniphila, Amuc_1100, mediates the metabolic benefits by activating Toll-Like Receptor 2 (TLR2).
The benefits of Akkermansia muciniphila are driven by its outer membrane protein Amuc_1100, which interacts with the immune system (TLR2). This suggests that future therapies might use just this protein rather than the whole bacterium.
GoodSupportsHIGH confidence
Among these proteins, Amuc_1100, implicated in the formation of pili by A. muciniphila, was one of the most abundant... This hypothesis was further confirmed by showing that a version of the genetically engineered protein (called Amuc_1100*) was effectively activating TLR2 and with the same magnitude as A. muciniphila.
Why this rating
Strong mechanistic evidence in mice using purified protein.
Source
Next-Generation Beneficial Microbes: The Case of Akkermansia muciniphila
Patrice D. Cani et al. · Frontiers in Microbiology · 2017
DOI 10.3389/fmicb.2017.01765
narrative_reviewCited 1,058×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Daily oral administration of live Akkermansia muciniphila (2.10^8 cells) improves metabolic health in high-fat diet-fed mice by restoring gut barrier function and reducing metabolic endotoxemia.Moderate
- Pasteurization of Akkermansia muciniphila enhances its metabolic benefits compared to live administration, likely due to the exposure of outer membrane proteins like Amuc_1100.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →